Cargando…
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
Despite current standard of care treatment, the period shortly after acute myocardial infarction (AMI) is associated with high residual cardiovascular (CV) risk, with high rates of recurrent AMI and CV death in the first 90 days following the index event. This represents an area of high unmet need t...
Autores principales: | Korjian, Serge, Kazmi, Syed Hassan A, Chi, Gerald, Kalayci, Arzu, Lee, Jane J, Talib, Usama, Wright, Samuel D, Duffy, Danielle, Kingwell, Bronwyn A, Mehran, Roxana, Ridker, Paul M, Gibson, C Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236524/ https://www.ncbi.nlm.nih.gov/pubmed/36787889 http://dx.doi.org/10.1093/ehjcvp/pvad014 |
Ejemplares similares
-
Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022) -
Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023) -
Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
por: Zheng, Bo, et al.
Publicado: (2022) -
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
por: Kalayci, Arzu, et al.
Publicado: (2022) -
Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021)